Log in

CMH neurologist weighs in on impact of new medication

Posted 7/14/23

The Food and Drug Administration (FDA) granted full approval to Leqembi, an Alzheimer’s drug, on Thursday, July 6, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease.

This item is available in full to subscribers.

Please log in to continue